One hundred one patients were randomized in a @:@ ratio to receive selumetinib , @ mg orally twice daily on a continual basis ( n = @ ) , or chemotherapy ( temozolomide , @ mg/m@ orally daily for @ of every @ days , or dacarbazine , @ mg/m@ intravenously every @ days -LSB- investigator choice -RSB- ; n = @ ) until disease progression , death , intolerable adverse effects , or withdrawal of consent .